Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients

被引:1
|
作者
Beltran-Bless, A. [1 ]
Murshed, M. [2 ]
Zakikhani, M. [3 ]
Kuchuk, I [1 ]
Bouganim, N. [1 ]
Robertson, S. [5 ,6 ]
Kekre, N. [1 ]
Vandermeer, L. [1 ]
Li, J. [3 ]
Addison, C. L. [4 ]
Rauch, F. [7 ]
Clemons, M. [1 ,4 ]
Kremer, R. [3 ]
机构
[1] Univ Ottawa, Ottawa Hosp, Dept Med, Div Med Oncol, Ottawa, ON, Canada
[2] McGill Univ, Shriners Hosp Children, Fac Dent, Dept Med, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Res Inst, Hlth Ctr, Montreal, PQ, Canada
[4] Ottawa Hosp Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada
[5] Ottawa Hosp, Dept Pathol, Ottawa, ON, Canada
[6] Univ Ottawa, Ottawa, ON, Canada
[7] McGill Univ, Dept Pediat Surg, Hlth Ctr, Montreal, PQ, Canada
来源
BONE REPORTS | 2021年 / 15卷
基金
加拿大健康研究院;
关键词
Bone-targeted agents; Breast cancer; Bone biopsy; Bone microarchitecture; Histomorphometry; Bone turnover; SKELETAL-RELATED EVENTS; TERMINAL PROPEPTIDE; VERTEBRAL FRACTURE; TURNOVER MARKERS; ZOLEDRONIC ACID; TARGETED AGENTS; DOUBLE-BLIND; I COLLAGEN; WOMEN; PINP;
D O I
10.1016/j.bonr.2021.101145
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite widespread use of repeated doses of potent bone-targeting agents (BTA) in oncology patients, relatively little is known about their in vivo effects on bone homeostasis, bone quality, and bone architecture. Traditionally bone quality has been assessed using a trans-iliac bone biopsy with a 7 mm "Bordier" core needle. We examined the feasibility of using a 2 mm "Jamshidi (TM)" core needle as a more practical and less invasive technique. Methods: Patients with metastatic breast cancer on BTAs were divided according to the extent of bone metastases. They were given 2 courses of tetracycline labeling and then underwent a posterior trans-iliac trephine biopsy and bone marrow aspirate. Samples were analyzed for the extent of tumor invasion and parameters of bone turnover and bone formation by histomorphometry. Results: Twelve patients were accrued, 1 had no bone metastases, 3 had limited bone metastases (LSM) (<3 lesions) and 7 had extensive bone metastases (ESM) (>3 lesions). Most of the primary tumors were estrogen receptor (ER)/progesterone receptor (PR) positive. The procedure was well tolerated. The sample quality was sufficient to analyze bone trabecular structure and bone turnover by histomorphometry in 11 out of 12 patients. There was a good correlation between imaging data and morphometric analysis of tumor invasion. Patients with no evidence or minimal bone metastases had no evidence of tumor invasion. Most had suppressed bone turnover and no detectable bone formation when treated with BTA. In contrast, 6 out of 7 patients with extensive bone invasion by imaging and evidence of tumor cells in the marrow had intense osteoclastic activity as measured by the number of osteoclasts. Of these 7 patients with ESM, 6 were treated with BTA with 5 showing resistance to BTA as demonstrated by the high number of osteoclasts present. 3 of these 6 patients had active bone formation. Based on osteoblast activity and bone formation, 3 out of 6 patients with ESM responded to BTA compared to all 3 with LSM. Compared to untreated patients, all patients treated with BTA showed a trend towards suppression of bone formation, as measured by tetracycline labelling. There was also a trend towards a significant difference between ESM and LSM treated with BTA, highly suggestive of resistance although limited by the small sample size. Discussion: Our results indicate that trans-iliac bone biopsy using a 2 mm trephine shows excellent correlation between imaging assessment of tumor invasion and tumor burden by morphometric analysis of bone tissues. In addition, our approach provides additional mechanistic information on therapeutic response to BTA supporting the current clinical understanding that the majority of patients with extensive bone involvement eventually fail to suppress bone turnover (Petrut B, et al. 2008). This suggests that antiresorptive therapies become less effective as disease progresses.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Improving metastatic bone pain management with ibandronate in patients with breast cancer
    Body, JJ
    Bergstrom, B
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S134 - S134
  • [22] Genes associated with breast cancer metastatic to bone
    Smid, Marcel
    Wang, Yixin
    Klijn, Jan G. M.
    Sieuwerts, Anieta M.
    Zhang, Yi
    Atkins, David
    Martens, John W. M.
    Foekens, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2261 - 2267
  • [23] Stress in Metastatic Breast Cancer: To the Bone and Beyond
    Lourenco, Catarina
    Conceicao, Francisco
    Jeronimo, Carmen
    Lamghari, Meriem
    Sousa, Daniela M.
    CANCERS, 2022, 14 (08)
  • [24] Comparison of biochemical markers of bone turnover in breast and prostate cancer patients with metastatic bone disease
    Lyubimova, Nina, V
    Pashkov, M. N.
    Kochergina, N., V
    TUMOR BIOLOGY, 2006, 27 : 110 - 110
  • [25] Replacement of the bone marrow with metastatic breast cancer
    Ohno, Hitoshi
    INTERNAL MEDICINE, 2007, 46 (08) : 531 - 532
  • [26] Skeletal related events in breast cancer patients with metastatic bone disease.
    Naqi, N
    Ilyas, M
    Hashim, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 55S - 55S
  • [27] Renal safety of intravenous ibandronate in breast cancer patients with metastatic bone disease
    Bergstrom, B
    Lyubimova, NV
    Pashkov, MV
    Kushlinsky, NE
    Lichinitser, MR
    BONE, 2005, 36 : S213 - S214
  • [28] Clinical significance of occult metastatic cells in bone marrow of breast cancer patients
    Braun, S
    Pantel, K
    ONCOLOGIST, 2001, 6 (02): : 125 - 132
  • [29] Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
    Cleeland, Charles
    von Moos, Roger
    Walker, Mark S.
    Wang, Yuanyuan
    Gao, Jianqing
    Chavez-MacGregor, Mariana
    Liede, Alexander
    Arellano, Jorge
    Balakumaran, Arun
    Qian, Yi
    SUPPORTIVE CARE IN CANCER, 2016, 24 (08) : 3557 - 3565
  • [30] LONG-TERM BONE MANAGEMENT BY BISPHOSPHONATE IN METASTATIC BREAST CANCER PATIENTS
    Watanabe, Junichiro
    Yonekura, Rika
    Hayashi, Tomomi
    Nishimura, Seiichiro
    Takahashi, Kaoru
    BREAST, 2013, 22 : S53 - S53